Katie E Lineburg

Dr. Katie E Lineburg

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in Blood
Verified
Journal Article
Closed access
PDF file
LMLucie Leveque-El Mouttie
Lucie Leveque-El Mouttie
MKMotoko Koyama
Motoko Koyama
LTLaetitia Le Texier
Laetitia Le Texier
KMKate A. Markey
Kate A. Markey
MCMelody Cheong
Melody Cheong
KMKelli P. A. MacDonald
Kelli P. A. MacDonald
Key Points: Acute GVHD leads to defective MHC class II antigen presentation by donor DC, leading to a failure of peripheral Treg homeostasis. Impaired Treg homeostasis results in chronic GVHD directly and can be alleviated by adoptive Treg transfer.

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
KLKatie E Lineburg
Katie E Lineburg
SSSriganesh Srihari
Sriganesh Srihari
MAMohammed Altaf
Mohammed Altaf
SSSrividhya Swaminathan
Srividhya Swaminathan
APArchana Panikkar
Archana Panikkar
CSCorey Smith
Corey Smith
Objectives: There is emerging evidence that SARS‐CoV‐2‐specific memory T‐cell responses are likely to provide critical long‐term protection against COVID‐19. Strategies to rapidly assess T‐cell responses are therefore likely to be important for assessing immunity in the global population.Methods: Here, we have developed a rapid immune‐monitoring strategy to assess virus‐specific memory T‐cell responses in the peripheral blood of COVID‐19 convalescent individuals. We validated SARS‐CoV‐2‐specific memory T‐cell responses detected in whole blood using in vitro expansion with SARS‐CoV‐2 proteins.Results: T‐cell immunity characterised by the production of IFN‐γ and IL‐2 could be consistently detected in the whole blood of recovered participants. T cells predominantly recognised structural SARS‐CoV‐2 proteins. In vitro expansion demonstrated that while CD8+ T cells recognised nucleocapsid protein, spike protein and ORF3a, CD4+ T cells more broadly targeted multiple SARS‐CoV‐2 proteins.Conclusion: These observations provide a timely monitoring approach for identifying SARS‐CoV‐2 cellular immunity and may serve as a diagnostic for the stratification of risk in immunocompromised and other at‐risk individuals.

7 November 2011 in Glia
Verified
Journal Article
Open access
PDF file
FCFatemeh Chehrehasa
Fatemeh Chehrehasa
JEJenny Ekberg
Jenny Ekberg
KLKatie E Lineburg
Katie E Lineburg
DADaniel Amaya
Daniel Amaya
AMAlan Mackay-Sim
Alan Mackay-Sim
James St JohnJames St John
James St John
Olfactory ensheathing cells (OECs) support the regeneration of olfactory sensory neurons throughout life, however, it remains unclear how OECs respond to a major injury. We have examined the proliferation and migration of OECs following unilateral bulbectomy in postnatal mice. S100ß‐DsRed and OMP‐ZsGreen transgenic mice were used to visualize OECs and olfactory neurons, respectively, and we used the thymidine analogue ethynyl deoxyuridine (EdU) to identify cells that were proliferating at the time of administration. Following unilateral bulbectomy, there was an initial phase of OEC proliferation throughout the olfactory pathway with a peak of proliferation occurring 2 to 7 days after the injury. A second phase of proliferation also occurred in which precursors localized within the olfactory mucosa divided to replenish the OEC population. We then tracked the positions of OECs that had proliferated and found that there was a progressive increase in OECs in the cavity for at least 12 to 16 days after injury which could not be accounted for solely by local proliferation of OECs within the cavity. These results suggest that OECs migrated from the peripheral olfactory nerve to populate the mass of cells that filled cavity left by bulbectomy. Our results demonstrate that following injury to the olfactory nervous system, the OEC population is replenished by migration of cells that arise from both local proliferation of OECs throughout the olfactory nerve pathway as well as from precursor cells in the olfactory mucosa.

1 January 2023 in Clinical & Translational Immunology
Verified
Journal Article
Open access
MTMarcus Zw Tong
Marcus Zw Tong
JSJulian D. J. Sng
Julian D. J. Sng
MCMeagan Carney
Meagan Carney
LCLucy Cooper
Lucy Cooper
SBSamuel Brown
Samuel Brown
Kirsty ShortKirsty Short
Kirsty Short
Objective: Class III obesity (body mass index [BMI] ≥ 40 kg m−2) significantly impairs the immune response to SARS‐CoV‐2 vaccination. However, the effect of an elevated BMI (≥ 25 kg m−2) on humoral immunity to SARS‐CoV‐2 infection and COVID‐19 vaccination remains unclear.Methods: We collected blood samples from people who recovered from SARS‐CoV‐2 infection approximately 3 and 13 months of post‐infection (noting that these individuals were not exposed to SARS‐CoV‐2 or vaccinated in the interim). We also collected blood samples from people approximately 5 months of post‐second dose COVID‐19 vaccination (the majority of whom did not have a prior SARS‐CoV‐2 infection). We measured their humoral responses to SARS‐CoV‐2, grouping individuals based on a BMI greater or less than 25 kg m−2.Results: Here, we show that an increased BMI (≥ 25 kg m−2), when accounting for age and sex differences, is associated with reduced antibody responses after SARS‐CoV‐2 infection. At 3 months of post‐infection, an elevated BMI was associated with reduced antibody titres. At 13 months of post‐infection, an elevated BMI was associated with reduced antibody avidity and a reduced percentage of spike‐positive B cells. In contrast, no significant association was noted between a BMI ≥ 25 kg m−2 and humoral immunity to SARS‐CoV‐2 at 5 months of post‐secondary vaccination.Conclusions: Taken together, these data showed that elevated BMI is associated with an impaired humoral immune response to SARS‐CoV‐2 infection. The impairment of infection‐induced immunity in individuals with a BMI ≥ 25 kg m−2 suggests an added impetus for vaccination rather than relying on infection‐induced immunity.

27 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
WTWen Juan Tu
Wen Juan Tu
MMMichelle Melino
Michelle Melino
JDJenny Dunn
Jenny Dunn
RMRobert D. McCuaig
Robert D. McCuaig
Helle Bielefeldt-OhmannHelle Bielefeldt-Ohmann
Helle Bielefeldt-Ohmann
SRSudha Rao
Sudha Rao
In vitro, ACE2 translocates to the nucleus to induce SARS-CoV-2 replication. Here, using digital spatial profiling of lung tissues from SARS-CoV-2-infected golden Syrian hamsters, we show that a specific and selective peptide inhibitor of nuclear ACE2 (NACE2i) inhibits viral replication two days after SARS-CoV-2 infection. Moreover, the peptide also prevents inflammation and macrophage infiltration, and increases NK cell infiltration in bronchioles. NACE2i treatment increases the levels of the active histone mark, H3K27ac, restores host translation in infected hamster bronchiolar cells, and leads to an enrichment in methylated ACE2 in hamster bronchioles and lung macrophages, a signature associated with virus protection. In addition, ACE2 methylation is increased in myeloid cells from vaccinated patients and associated with reduced SARS-CoV-2 spike protein expression in monocytes from individuals who have recovered from infection. This protective epigenetic scarring of ACE2 is associated with a reduced latent viral reservoir in monocytes/macrophages and enhanced immune protection against SARS-CoV-2. Nuclear ACE2 may represent a therapeutic target independent of the variant and strain of viruses that use the ACE2 receptor for host cell entry.

1 January 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
KLKatie E Lineburg
Katie E Lineburg
MNMichelle A Neller
Michelle A Neller
GAGeorge R Ambalathingal
George R Ambalathingal
LTLaetitia Le Texier
Laetitia Le Texier
JRJyothy Raju
Jyothy Raju
CSCorey Smith
Corey Smith
Objectives: With the ongoing emergence of SARS‐CoV‐2 variants and potential to evade vaccine‐induced neutralisation, understanding the magnitude and breadth of vaccine‐induced T‐cell immunity will be critical for the ongoing optimisation of vaccine approaches. Strategies that provide a rapid and easily translatable means of assessing virus‐specific T‐cell responses provide an opportunity to monitor the impact of vaccine rollouts in the community. In this study, we assessed whether our recently developed SARS‐CoV‐2 whole‐blood assay could be used effectively to analyse T‐cell responses following vaccination.Methods: Following a median of 15 days after the first dose of the ChAdOx1‐S (AstraZeneca®) vaccine, peripheral blood was isolated from 58 participants. Blood was incubated overnight with an overlapping set of spike protein peptides and assessed for cytokine production using a cytometric bead array.Results: The majority of vaccine recipients (51/58) generated a T helper 1 response (IFN‐γ and/or IL‐2) following a single dose of ChAdOx1‐S. The magnitude of the IFN‐γ and IL‐2 response strongly correlated in vaccine recipients. While the production of other cytokines was evident in individuals who did not generate IFN‐γ and IL‐2, they showed no correlation in magnitude, nor did we see a correlation between sex or age and the magnitude of the response.Conclusions: The whole‐blood cytokine assay provides a rapid approach to assessing T‐cell immunity against SARS‐CoV‐2 in vaccine recipients. While the majority of participants generated a robust SARS‐CoV‐2‐specific T‐cell response following their first dose, some did not, demonstrating the likely importance of the booster dose in improving T‐cell immunity.